RTI Biologics, Inc. (RTIX) Tops Q1 EPS by 2c; Boosts Outlook
Get Alerts RTIX Hot Sheet
Join SI Premium – FREE
RTI Biologics, Inc. (NASDAQ: RTIX) reported Q1 EPS of $0.01, $0.02 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $60.7 million versus the consensus estimate of $55.4 million.
RTI Biologics, Inc. sees FY2014 EPS of $0.07-$0.09, versus prior guidance of $0.06-$0.08 and the consensus of $0.07. RTI Biologics, Inc. sees FY2014 revenue of $248-253 million, versus prior guidance of $245-250 million and the consensus of $236.80 million.
For earnings history and earnings-related data on RTI Biologics, Inc. (RTIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bristol-Myers Squibb (BMY) stock slips despite earnings beat
- Kirby Corp. (KEX) Tops Q1 EPS by 21c, provides outlook
- EMCOR Group (EME) Tops Q1 EPS by 133c, raises guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!